{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-009006","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.329489+00:00","generated_at":"2026-06-05T03:21:53.065222+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cumberland Pharma reports 2023 net loss of $6.3M; revenue $40M; Caldolor labeling expanded to infants","bullets":["Net loss $6.3M for 2023, includes $3.3M non-cash charge on product discontinuation; adjusted earnings $2.4M ($0.17/share).","Revenue $40M from four brands: Kristalose $16M, Vibativ $8.8M, Sancuso $8.1M, Caldolor $4.3M.","FDA approved expanded Caldolor labeling for infants 3-6 months; only non-opioid injectable for pain/fever in that age group.","NOPAIN Act expected to provide favorable CMS reimbursement for Caldolor starting 2025; company submitted request.","Ifetroban Phase II trials ongoing for DMD, scleroderma, IPF; FDA grants >$1M; oral capsule study initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-009006","json":"https://secwatch.observer/filing/0001628280-24-009006.json","markdown":"https://secwatch.observer/filing/0001628280-24-009006.md","text":"https://secwatch.observer/filing/0001628280-24-009006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/0001628280-24-009006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/cpix-20240305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:21:53.065222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ea424fc86ab0637798fe9c246d779332865dc27","claim":"CUMBERLAND PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 5, 2024, Cumberland Pharmaceuticals Inc. (the \"Company\") issued a press release which provided a company update and the financial results for the three months and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024009006/0001628280-24-009006-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}